Literature DB >> 3924606

Prophylaxis of Pseudomonas aeruginosa infections in leukopenic mice by a combination of active and passive immunization.

D Martinez, L T Callahan.   

Abstract

Mice rendered leukopenic with cyclophosphamide and then challenged with viable Pseudomonas aeruginosa were used to determine the protective efficacy of active immunization against exotoxin A and of passive immunization with human antiserum to Escherichia coli J5, a rough mutant of Escherichia coli O111:B4. Neither treatment alone provided a greater degree of protection than its respective control. However, the combination of these treatments produced a moderate, yet consistent, increase in the survival of infected immunosuppressed mice.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924606     DOI: 10.1007/BF02013595

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   5.103


  25 in total

1.  Passive immunization against the local Shwartzman reaction.

Authors:  A I Braude; H Douglas
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

2.  Treatment of gram-negative bacteremia with antiserum to core glycolipid II. A controlled trial of antiserum in patients with bacteremia.

Authors:  J A McCutchan; E J Ziegler; A I Braude
Journal:  Eur J Cancer       Date:  1979       Impact factor: 9.162

3.  Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.

Authors:  E J Ziegler; J A McCutchan; H Douglas; A I Braude
Journal:  Trans Assoc Am Physicians       Date:  1975

4.  Pseudomonas aeruginosa vasculitis and bacteremia following conjunctivitis: a simple model of fatal pseudomonas infection in neutropenia.

Authors:  E J Ziegler; H Douglas
Journal:  J Infect Dis       Date:  1979-03       Impact factor: 5.226

5.  Type-specific vs. cross-protective vaccination for gram-negative bacterial pneumonia.

Authors:  J E Pennington; E Menkes
Journal:  J Infect Dis       Date:  1981-12       Impact factor: 5.226

6.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

7.  Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone.

Authors:  S E Greisman; J B DuBuy; C L Woodward
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

8.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors:  M Pollack
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

9.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.609

10.  Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids.

Authors:  O R Pavlovskis; D C Edman; S H Leppla; B Wretlind; L R Lewis; K E Martin
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.